Previous 10 | Next 10 |
TEL AVIV, Israel, March 16, 2022 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), a global developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prevention, announced today that it will host a Key Opinion Leade...
InspireMD, Inc. (NSPR) Q4 2021 Earnings Conference Call March 8, 2022 08:30 AM ET Company Participants Chuck Padala - Managing Director, LifeSci Advisors Marvin Slosman - Chief Executive Officer Craig Shore - Chief Financial Officer Conference Call Participants Ben Haynor - Alliance Global Pr...
InspireMD press release (NASDAQ:NSPR): Q4 GAAP EPS of -$0.53. Revenue of $1.38M (+762.5% Y/Y). “We enter 2022 with tremendous momentum, anticipating growth of CGuard, continuing pipeline development and advancing the growing body of evidence demonstrating CGuards’s superiority i...
- CGuard™ Revenue Generated 87.5% growth over Q4’20 and 55.9% Year-over-Year –- - Published CGuard Clinical trial results in Journals of the American College of Cardiology - - Established Reimbursement Approval for CGuard from the French National Aut...
InspireMD (NASDAQ:NSPR) is scheduled to announce Q4 earnings results on Tuesday, March 8th, before market open. The consensus EPS Estimate is -$0.78 (-680.0% Y/Y) and the consensus Revenue Estimate is $1.3M (+712.5% Y/Y). For further details see: InspireMD Q4 2021 Earnings Preview
- CGuard ™ Carotid Stent will now be a treatment option in the stenting plus medical therapy arm of the trial for patients - - CREST-2 Trial is sponsored by the National Institute of Neurological Disorders and Stroke (NINDS) and actively engaged at more than 140 stu...
-Earnings Conference Call to be held Tuesday, March 8, 2022, at 8:30 a.m. ET- TEL AVIV, Israel, Feb. 22, 2022 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease ...
TEL AVIV, Israel, Feb. 15, 2022 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), a global developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease (CAD) and stroke prevention, today announced the appointment of Adnan Siddiqu...
TEL AVIV, Israel, Jan. 27, 2022 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for prevention of stroke caused by Carotid Artery Disease (CAD), today announced that Marvin Slosman, Chief Executive Officer, is schedul...
TEL AVIV, Israel, Jan. 18, 2022 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for prevention of stroke caused by Carotid Artery Disease (CAD), today announced that a live case demonstration featuring CGuard™ ...
News, Short Squeeze, Breakout and More Instantly...
Series H warrants exercisable following release of positive outcomes results related to one-year follow-up from the Company’s C-GUARDIANS pivotal trial. Participating warrant holders include Marshall Wace, OrbiMed, Rosalind, Nantahala, Soleus, Velan, and certain InspireMD Board m...
Data demonstrate lowest reported primary endpoint event rate of 1.95% through twelve months post-procedure for any carotid stent or embolic protection device pivotal trial Study results to support a Premarket Approval (PMA) application to FDA in H2 2024 U.S. commercial launch of...